Obstetrics, gynecology and reproductive medicine guidelines

HIV/AIDS

PubMed Free Full Text

Anti-HIV agents

Botswana

• Ministry of Health Botswana
  • Botswana HIV/AIDS Treatment Guidelines [2008]

Canada

• B.C. Centre for Excellence in HIV/AIDS
  • Adult Therapeutic Guidelines [2009]
  • Drug Treatment Program

International

• Cochrane Library
  • Therapeutic drug monitoring of antiretrovirals for people with HIV
  • Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults
  • Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings
  • Herbal medicines for treating HIV infection and AIDS

• Lancet
  • Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies [2009]

• UNAIDS: The Joint UN Programme on HIV/AIDS
  • HIV Treatment

Italy

• Journal of Antimicrobial Chemotherapy
  • Key questions in antiretroviral therapy: Italian Consensus Workshop (2005) [2006]

• New Microbiologica
  • Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons [2011]

Malaysia

• Ministry of Health Malaysia
  • Consensus on Antiretroviral Treatment (2nd Edition) [2001]

Rwanda

• Ministry of Health Rwanda
  • HIV/AIDS Treatment and Care Plan 2003-2007 [2003]

South Africa

• Department of Health South Africa
  • National Antiretroviral Treatment Guidelines - 2004 [2004]

• Health Systems Trust
  • Providing Antiretroviral Treatment in Southern Africa - A Literature Review [2004]
  • Antiretroviral treatment roll-out policy is in place - now for the implementation challenges [2004]

Spain

• Journal of Antimicrobial Chemotherapy
  • Once-daily antiretroviral therapy: Spanish Consensus Statement [2006]

Uganda

• Ministry of Health Uganda
  • National Antiretroviral Treatment and Care Guidelines for Adults, Adolescents, and Children [2009]

United Kingdom

• British HIV Association
  • British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010 [2010]
  • Addendum to BHIVA Treatment Guidelines [2009]
  • British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 [2008]
  • Adherence (2001) [2001]

United States of America

• Body: An AIDS and HIV Information Resource
  • HIV/AIDS Treatment

• CDC HIV/AIDS
  • Treatment

• Food and Drug Administration
  • HIV and AIDS Activities

• HIV InSite - University of California San Francisco
  • HIV InSite Treatment

• International AIDS Society-USA
  • Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel [2010]
  • Antiretroviral Therapy: New Drugs, Formulations, Ideas, and Strategies [2009]
  • Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel [2008]
  • Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel [2006]

• National Guideline Clearinghouse
  • New antiretroviral drugs: maraviroc, raltegravir, etravirine, and rilpivirine. New York State Department of Health [2011]
  • Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (U.S.) [2011]
  • HIV drug - drug interactions. New York State Department of Health [2010]
  • Expert Commentaries: Recommendations for Initiating Antiretroviral Therapy Reflect Need for Further Research [2010]
  • Antiretroviral therapy. New York State Department of Health [2010]
  • Antiretroviral therapy for HIV infection in adults and adolescents. WHO [2010]
  • Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America [2009]
  • Drug-drug interactions between HAART, medications used in substance use treatment, and recreational drugs. New York State Department of Health [2008]

• New York State Department of Health AIDS Institute
  • New Antiretroviral Drugs: Maraviroc, Raltegravir, Etravirine, and Rilpivirine [2011]
  • HIV Drug-Drug Interactions [2010]
  • Antiretroviral Therapy [2010]

WHO

• WHO Regional Office for Africa
  • Completion report of Treatment Acceleration Project (TAP) 2005-2008 [2009]

• WHO Regional Office for Europe
  • Patient evaluation and antiretroviral treatment for adults and adolescents : clinical protocol for the WHO European Region [2012]
  • Regional consultation on revision of the clinical protocols "HIV/AIDS treatment and care" for the WHO European Region : technical report, 7 October 2010, Kiev, Ukraine [2010]
  • ART failure and strategies for switching ART regimens in the WHO European Region [2008]

• WHO Regional Office for South-East Asia
  • Scaling-up Antiretroviral Treatment - Lessons learnt from Thailand [2007]
  • Management of HIV Infection and Antiretroviral Therapy in Adults and Adolescents – A Clinical Manual [2007]
  • Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS [2007]
  • HIV Care and ART Recording and Reporting System Draft Training Toolkit [2006]
  • Antiretrovirals for HIV: A compilation of facts and product information [2006]
  • Expanding Access to HIV/AIDS Treatment: Mission report Indonesia, 19-31 January 2004 [2005]
  • Expanding Access to HIV/AIDS Treatment: Mission report India, 8-12 December 2003 [2005]

• World Health Organization
  • Global forecasts of antiretroviral demand 2012-2013 : joint WHO/UNAIDS annual consultation with pharmaceutical companies [2012]
  • 2010 ART guidelines for adults and adolescents - evidence map [2012]
  • Short-term priorities for antiretroviral drug optimization: meeting report [2011]
  • Country experiences in implementing patient monitoring systems for HIV care and antiretroviral therapy in Ethiopia, Guyana and India : an overview of best practices and lessons learned [2010]
  • Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 revision) [2010]
  • Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents [2009]
  • WHO consultation on ART failure in the context of a public health approach [2008]
  • Demand forecast for antiretroviral drugs in low and middle-income countries, 2007-2008 [2008]
  • Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach [2007]
  • Interventions to address HIV in prisons: HIV care, treatment and support [2007]
  • Patient monitoring guidelines for HIV care and antiretroviral therapy [2006]
  • Country-enhanced monitoring and evaluation for antiretroviral therapy scale-up: analysis and use of strategic information in Botswana [2006]
  • Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2006 revision) [2006]
  • Introducing ARV Therapy in the Public Sector in Botswana [2004]
  • Antiretroviral therapy in primary health care: experience of the chiradzulu programme in Malawi [2004]
  • Handbook on Access to HIV/AIDS-Related Treatment [2003]
  • A public health approach for scaling up antiretroviral treatment [2003]
  • Scaling up antiretroviral therapy in resource-limited settings [2002]
  • Antiretroviral therapy

Articles in journals

• AIDS Care
  • A Systematic Review Comparing Antiretroviral Adherence Descriptive and Intervention Studies [2009]

• Antimicrobial Agents and Chemotherapy
  • Insertions in the Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Genes: Clinical Impact and Molecular Mechanisms [2005]
  • Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase [2005]
  • Molecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase [2003]

• Antiviral Chemistry & Chemotherapy
  • Antiretroviral therapy in macrophages: implication for HIV eradication [2009]

• Antiviral Research
  • The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic [2009]

• Antiviral Therapy
  • Simplification Strategies to Reduce Antiretroviral Drug Exposure: Progress and Prospects [2009]

• Archives of Internal Medicine
  • Standard Care Impact on Effects of Highly Active Antiretroviral Therapy Adherence Interventions: A Meta-analysis of Randomized Controlled Trials [2010]

• BMC Public Health
  • Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review [2007]

• Brazilian Journal of Infectious Diseases
  • The Place of protease inhibitors in antiretroviral treatment [2009]

• British Medical Journal
  • Patients' readiness to start highly active antiretroviral treatment for HIV [2005]
  • Antiretroviral therapy in Africa [2004]

• Bulletin of the World Health Organization
  • How should access to antiretroviral treatment be measured? [2011]
  • Universal antiretroviral treatment: the challenge of human resources [2010]
  • Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases [2009]

• Cadernos de Saúde Pública
  • Antiretroviral manufacturers and the challenge of universal access to drugs through the Brazilian National STD/AIDS Program [2009]

• Clinical and Vaccine Immunology
  • Expanding Role of Circulating Adhesion Molecules in Assessing Prognosis and Treatment Response in Human Immunodeficiency Virus Infection [2004]

• Clinical Infectious Diseases
  • Retaining HIV-Infected Patients in Care: Where Are We? Where Do We Go from Here? [2010]
  • The Management of Treatment-Experienced HIV-Infected Patients: New Drugs and Drug Combinations [2009]
  • The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options [2009]
  • Raltegravir: The First HIV Type 1 Integrase Inhibitor [2009]
  • Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhbitor [2009]

• Clinical Pharmacokinetics
  • Drug Interactions with New and Investigational Antiretrovirals [2009]

• Current HIV/AIDS Reports
  • When to Start Antiretroviral Therapy [2010]

• Current Opinion in HIV and AIDS
  • Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors [2009]
  • HIV-1 Entry Inhbitors: An Overview [2009]
  • Defining Treatment Failure in Resource-Rich Settings [2009]
  • CCR5 Monoclonal Antibodies for HIV-1 Therapy [2009]

• Current Opinion in Structural Biology
  • Peptides in the Treatment of AIDS [2009]

• Expert Opinion on Biological Therapy
  • Prospects for antisense peptide nucleic acid (PNA) therapies for HIV [2009]
  • Novel HIV-1 Therapeutics through Targeting Altered Host Cell Pathways [2009]

• Expert Opinion on Therapeutic Targets
  • Virus Maturation as a Novel HIV-1 Therapeutic Target [2009]

• Expert Reviews
  • Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics [2010]

• FEBS Journal
  • Piecing together the structure of retroviral integrase, an important target in AIDS therapy [2009]

• HIV Clinical Trials
  • Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen [2009]
  • Causes and consequences of incomplete HIV RNA suppression in clinical trials [2009]
  • Access to Medications and Medical Care After Participation in HIV Clinical Trials: A Systematic Review of Trial Protocols and Informed Consent Documents [2009]

• Indian Journal of Medical Research
  • Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives [2004]

• International Journal of Nanomedicine
  • Progress in antiretroviral drug delivery using nanotechnology [2010]

• Japanese Journal of Infectious Diseases
  • The interaction of HIV-1 with the host factors [2005]

• Journal of Antimicrobial Chemotherapy
  • Novel strategies to treat antiretroviral-naive HIV-infected patients [2009]
  • New therapeutic strategies for raltegravir [2009]
  • Eradication of HIV: current challenges and new directions [2009]
  • Efavirenz: a decade of clinical experience in the treatment of HIV [2009]
  • Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable [2009]
  • HIV infection in older patients in the HAART era [2006]
  • Dawn of non-nucleoside inhibitor-based anti-HIV microbicides [2006]
  • Benefits and concerns of simplification strategies in HIV-infected patients [2006]
  • Treatment of advanced HIV infection [2003]
  • Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection [2003]
  • The mechanisms that control intracellular penetration of the HIV protease inhibitors [2003]
  • Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART [2003]
  • HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity [2003]

• Journal of Clinical Investigation
  • Acute HIV revisited: new opportunities for treatment and prevention [2004]

• Journal of Immunology
  • PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention [2009]

• Journal of Infectious Diseases
  • Clinical Management of Acute HIV Infection: Best Practice Remains Unknown [2010]

• Journal of Postgraduate Medicine
  • Future implications: Compliance and failure with antiretroviral treatment [2006]

• Journal of the American Board of Family Practice
  • Treatment of AIDS and HIV-Related Conditions—2002: Antiretroviral Therapy [2002]

• Medical Journal of Australia
  • Ten years of highly active antiretroviral therapy for HIV infection [2007]

• Nanomedicine
  • Emerging nanotechnology approaches for HIV/AIDS treatment and prevention [2010]

• Pharmacogenomics
  • Pharmacogenomics of CYP3A: considerations for HIV treatment [2009]

• PLoS Medicine
  • Antiretroviral Therapy for Prevention of HIV Infection: New Clues From an Animal Model [2008]
  • Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review [2007]
  • Training and HIV-Treatment Scale-Up: Establishing an Implementation Research Agenda [2006]
  • Modelling the Impact of Antiretroviral Use in Resource-Poor Settings [2006]
  • Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa [2006]
  • Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators [2006]

• Retrovirology
  • Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors [2009]
  • Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies [2009]
  • Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature [2008]

• Revista de Saúde Pública
  • Quality of life and adherence to HAART in HIV-infected patients [2010]

• Science
  • The Challenge of Finding a Cure for HIV Infection [2009]

• Topics in HIV Medicine
  • When to start antiretroviral therapy [2010]
  • What do we need to do to cure HIV infection [2010]
  • Advances in antiretroviral therapy [2010]
  • Structured treatment interruptions--new findings [2006]
  • Drug-drug interactions that matter [2006]
  • Current concepts in antiretroviral therapy failure [2006]
  • Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes [2005]
  • Drug-drug interactions and the pharmacotherapy of HIV infection [2005]
  • Unwelcome Guests With Master Keys: How HIV Enters Cells and How It Can Be Stopped [2004]
  • Initiation of Antiretroviral Therapy: Implications of Recent Findings [2004]
  • Approaches to immune reconstitution in HIV infection [2003]
  • Antiretroviral therapy: select lessons from recent studies [2003]
  • Antiretroviral adherence interventions: a review of current literature and ongoing studies [2003]
  • Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring [2003]

• Trends in Pharmacological Sciences
  • Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development [2009]

{Related topics}

• Guidelines
  • HIV/AIDS
  • Anti-HIV agents: post-exposure prophylaxis
  • Anti-HIV agents: microbicides
  • Anti-HIV agents: drug resistance
  • Anti-HIV agents: adverse events, complications